What does this research mean for the field?

Adjunctive administration of the selective P2Y12-receptor antagonist AR-C69931MX with thrombolytic therapy prevents platelet-mediated thrombosis, decreases reocclusion rates, and significantly improves myocardial tissue perfusion. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to investigate the role of AR-C69931MX in preventing platelet aggregation and improving myocardial tissue perfusion during reperfusion therapy.

February 1, 2003Arteriosclerosis Thrombosis and Vascular BiologyOpen Access

Blockade of the Platelet P2Y ₁₂ Receptor by AR-C69931MX Sustains Coronary Artery Recanalization and Improves the Myocardial Tissue Perfusion in a Canine Thrombosis Model

View Full Paper

Ask AI

Bookmark

Why the study?

Does AR-C69931MX reduce reocclusion and improve myocardial tissue perfusion in a canine thrombosis model receiving thrombolytic therapy?

Key Points

This research aims to investigate the role of AR-C69931MX in preventing platelet aggregation and improving myocardial tissue perfusion during reperfusion therapy.
Canine coronary electrolytic injury thrombosis model utilized.
Thrombolytic therapy with t-PA provided 30 minutes post-thrombus formation; AR-C69931MX administered before t-PA for 2 hours in treatment group.
Myocardial tissue perfusion assessed using colored microspheres and real-time echocardiography.
AR-C69931MX treatment significantly reduced reocclusion and cyclic flow variations (P<0.05).
Myocardial tissue flow improved at 20 and 120 minutes post-reflow with AR-C69931MX, compared to stationary perfusion levels in placebo (P<0.05).
AR-C69931MX effectively blocked ADP-mediated platelet aggregation, enhancing reperfusion time.

Structured PICO

Does AR-C69931MX reduce reocclusion and improve myocardial tissue perfusion in a canine thrombosis model receiving thrombolytic therapy?

Population

Canine coronary electrolytic injury thrombosis model

Intervention

AR-C69931MX (selective P2Y12-receptor antagonist) 4 micro g x kg(-1) x min(-1) intravenously for 2 hours, given 10 minutes before t-PA administration. All animals received heparin (80 U/kg bolus followed by 17 U x kg(-1) x h(-1) infusion).

Comparator

Saline intravenously for 2 hours, given 10 minutes before t-PA administration. All animals received heparin (80 U/kg bolus followed by 17 U x kg(-1) x h(-1) infusion).

Outcome

Incidences of reocclusion, cyclic flow variation, and myocardial tissue perfusionsurrogate

Adjunctive administration of the P2Y12 antagonist AR-C69931MX with t-PA reduces reocclusion and improves myocardial tissue perfusion in a canine thrombosis model.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports adjunctive P2Y12 antagonism in thrombolysis models; leaves open translation to human reperfusion.

Cite This Study

Wang et al. (2003) studied this question.

synapsesocial.com/papers/6a19666bf3c200df10585065 https://doi.org/10.1161/01.atv.0000052669.50791.0b

Topics

Dual antiplatelet therapy Echocardiography

View Full Paper

Ask AI

Bookmark

Blockade of the Platelet P2Y ₁₂ Receptor by AR-C69931MX Sustains Coronary Artery Recanalization and Improves the Myocardial Tissue Perfusion in a Canine Thrombosis Model

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Blockade of the Platelet P2Y ₁₂ Receptor by AR-C69931MX Sustains Coronary Artery Recanalization and Improves the Myocardial Tissue Perfusion in a Canine Thrombosis Model

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider